Keisuke Kosugi

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial

Kohjiro Ueki, Takayoshi Sasako, Yukiko Okazaki et al. · The Lancet Diabetes & Endocrinology · 2017 · 309 citations

Medicine, Cardiology, Internal Medicine +13

Glycated Albumin is a Better Indicator for Glucose Excursion than Glycated Hemoglobin in Type 1 and Type 2 Diabetes

Kazutomi Yoshiuchi, Munehide Matsuhisa, Naoto Katakami et al. · Endocrine Journal · 2008 · 193 citations · Full text

Medicine, Biochemistry, Endocrinology +14

Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)

Tomoya Mita, Naoto Katakami, Hidenori Yoshii et al. · Diabetes Care · 2015 · 163 citations

Medicine, Pharmacology, Pharmacotherapy +17

Decreased Endogenous Secretory Advanced Glycation End Product Receptor in Type 1 Diabetic Patients

Naoto Katakami, Munehide Matsuhisa, Hideaki Kaneto et al. · Diabetes Care · 2005 · 157 citations · Full text

Medicine, Endocrinology, Internal Medicine +13

Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE)

Tomoya Mita, Naoto Katakami, Toshihiko Shiraiwa et al. · Diabetes Care · 2016 · 141 citations

Medicine, Endocrinology, Pharmacology +17